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Macrophages, cytokines and beta-cell death in Type 2 diabetes
Abstract
The pathology of islets from patients with Type 2 diabetes displays an inflammatory process
characterized by the presence of immune cell infiltration, cytokines, apoptotic cells, amyloid deposits
and, eventually, fibrosis. Indeed, analysis of beta-cells from patients with Type 2 diabetes displays
increased IL-1beta (interleukin 1beta) expression. Furthermore, increased islet-associated macrophages
are observed in human Type 2 diabetic patients and in most animal models of diabetes. Importantly,
increased numbers of macrophages are detectable very early in high-fat-fed mice islets, before the onset
of diabetes. These immune cells are probably attracted by islet-derived chemokines, produced in
response to metabolic stress, and under the control of IL-1beta. It follows that modulation of intra-islet
inflammatory mediators, particularly interleukin-1beta, may prevent islet inflammation in Type 2
diabetes and therefore presents itself as a promising therapeutic approach.
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Abstract
The pathology of islets from patients with Type 2 diabetes displays an inﬂammatory process characterized
by the presence of immune cell inﬁltration, cytokines, apoptotic cells, amyloid deposits and, eventually,
ﬁbrosis. Indeed, analysis of β-cells from patients with Type 2 diabetes displays increased IL-1β (interleukin
1β) expression. Furthermore, increased islet-associated macrophages are observed in human Type 2 diabetic
patients and in most animal models of diabetes. Importantly, increased numbers of macrophages are de-
tectable very early in high-fat-fed mice islets, before the onset of diabetes. These immune cells are probably
attracted by islet-derived chemokines, produced in response to metabolic stress, and under the control of IL-
1β. It follows thatmodulation of intra-islet inﬂammatorymediators, particularly interleukin-1β, may prevent
islet inﬂammation in Type 2 diabetes and therefore presents itself as a promising therapeutic approach.
Introduction
In this review, we present evidence for the presence of islet
inflammation in patients with Type 2 diabetes. Indeed, the
pathology of the islet in this condition is characterized by
the presence of immune cell infiltration, cytokines, Fas up-
regulation, nuclear factor κB (NF-κB) activation, apoptotic
cells, amyloid deposits and, eventually, fibrosis. Although
someof these changes have alreadybeendiscussed extensively
elsewhere (for reviews see [1,2]), in the present article, we
will focus on the role of IL (interleukin)-1β, immune cell
infiltration and clinical consequences.
Locally produced IL-1β plays an integral
role in the deleterious effects of high
glucose and a Type 2 diabetic milieu on
human pancreatic islets
Most of the knowledge of the properties of the IL-1 family
is derived from the field of immunology where IL-1β
was reported to have some unique features not shared by
other chemokines and cytokines [3,4]. Most notably, the
signal transduction pathway via the IL-1 receptor (type I) is
unusually effective. Indeed, fewer than ten molecules of IL-
1β bound per cell can induce biological responses that could
consequently be observed at concentrations 10–100-fold less
than that of the dissociation constant. Because of its potent
cytotoxic effect on cells [5], several ‘road guards’ tightly con-
trol the processing, release and receptor binding of IL-1β to
target cells. First, unlike other secreted cytokines, IL-1β does
not have a leader sequence and has to be processed from
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pro-IL-1β to IL-1β by intracellular inflammasomes before
secretion [6]. Secondly, once secreted, IL-1β associates with
binding proteins [7]. These IL-1β-binding proteins are also
the reason conventional ELISA detection of IL-1β is prob-
lematic and leads to underestimation of IL-1β concentrations
[8]. Thirdly, IL-1β-producing cells also synthesize their own
antagonist IL-1RA (IL-1 receptor antagonist), which binds
to the IL-1 receptor without having agonistic properties and
therebymodulates inflammatory responses [9]. The low level
of expression and the aformentioned ‘road guards’ render
IL-1β protein difficult to detect [3].
The spectrum of IL-1β-producing cells is very wide;
classically, IL-1β production was observed by activated
immune cells, but it was also shown to be expressed consti-
tutively and at very low levels by many different cell
types such as skin keratinocytes and mucosal, hypothalamic,
glial and vascular smooth muscle cells [9]. In islets, IL-1β
expression has been demonstrated in resident islet lymphoid
cells [10,11], ductal cells and islet vascular endothelial cells
[12], as well as insulin-producing β-cells [11,13,14]. It has
been proposed that intra-islet expression of inflammatory
cytokines, particularly IL-1β, contributes to β-cell gluco-
toxicity in the pathogenesis of Type 2 diabetes [13]. This
hypothesis was based on observations of increased IL-1β
expression in pancreatic sections of patients with Type 2
diabetes by immunofluorescence andby in situhybridization,
as well as in islets from the hyperglycaemic Psammomys
obesus [13]. Furthermore, high glucose concentrations in vitro
induced IL-1β release in most, but not all, human islet cell
preparations, followed by impaired insulin secretion and
apoptosis. In an attempt to elucidate the reason for this
variable result, this studywas repeated recently and expanded
upon under defined conditions [15]. Cultured human islets
exposed for 4 days to elevated glucose concentrations
exhibited increased IL-1β mRNA levels in six out of 12 islet
batches. Islet preparations where glucose did not increase
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IL-1β mRNA displayed higher basal IL-1β mRNA levels
than responsive preparations, and there was a significant
negative correlation between basal IL-1β mRNA levels and
glucose-stimulated IL-1βmRNA.Furthermore, the ability of
elevated glucose to increase islet IL-1β mRNA was masked
in the presence of increased concentrations of IL-1β. IL-1β
expression was increased by IL-1β auto-stimulation in whole
islet cultures andFACS-purified humanβ-cells and decreased
by the addition of IL-1RA. Auto-stimulation of IL-1β
mRNA was transient and NF-κB-dependent. High glucose
concentrations regulated IL-1β dually, by decreasing endo-
genous IL-1RA expression and by increasing IL-1β mRNA
via promotion of IL-1β auto-stimulation. Importantly, islet-
derived IL-1βwas shown tobebiologically active, as reflected
by the ability to induce the production of the inflammatory
factors IL-8 and IL-6. Finally, a gene array analysis of
near pure populations of β-cells obtained by laser-capture
microdissection revealed increased IL-1β mRNA in patients
with Type 2 diabetes compared with controls. The gene array
screening was validated by real-time PCR, confirming IL-1β
up-regulation in β-cells of patients with Type 2 diabetes.
Macrophages in islets of patients with
Type 2 diabetes
Pancreatic islets from Type 2 diabetes patients are known
to present with amyloid deposits, fibrosis and increased
cell death [16–19]. Furthermore, and as mentioned above,
cytokines and chemokines are released from islets exposed
to metabolic stress, partly under the control of IL-1β.
These events are typically associated with an inflammatory
response, and it was therefore expected that the pancreatic
islet in Type 2 diabetes is associated with immune cell
infiltration. Surprisingly, it is only recently that the first
study demonstrating increased islet macrophage infiltration
in patients with Type 2 diabetes was published [20]. Increased
islet-associated immune cells were also observed in a variety
of animal models of this disease including the GK (Goto-
Kakizaki) rat [21], the high-fat-diet fed and db/db mouse
[20], and the Cohen diabetic rat [22].Whether the presence of
macrophages is causative of Type 2 diabetes islet pathology
requires further investigation. Of note is the observation
that increased numbers of macrophages were detectable
very early in high-fat-fed mouse islets, before the onset of
diabetes. Possibly, early infiltration of macrophages may be
beneficial to islet function [20] and plasticity [23]. However,
as the disease progresses, macrophages may become activated
[22] and play a role in accelerating pancreatic islet cell
dysfunction and death. The presence of macrophages may
also be a consequence of β-cell death, acting to phagocytose
dead islet tissue. To this end, macrophages were not detected
in the vicinity of apoptotic cells [20].
The concept that macrophages are an integral part of the
islet pathology in Type 2 diabetes and not merely scavenger
cells is supported by their possible mechanism of attraction
[20]. Indeed, increased islet-derived inflammatory factors
are produced and released by islets exposed to a Type 2
diabetic milieu (high glucose and/or non-esterified fatty
acids) and by islets isolated from high-fat-fed mice, including
IL-6, IL-8, chemokine KC (keratinocyte chemoattractant),
G-CSF (granulocyte colony-stimulating factor) and MIP-1α
(macrophage inflammatoryprotein 1α). The specificity of this
response was demonstrated by direct comparison with non-
islet pancreatic tissue, which fails to display such a response
tometabolic stress. Also, induction of islet cell death by other
means (streptozotocin and staurosporine) does not increase
chemokine release. Finally, IL-8 has emerged as a possible
key mediator of immune cell attraction to human Type 2
diabetic islets, although this will need in vivo confirmation.
The role of IL-1β with respect to this Type 2 diabetic
islet inflammatory response has recently been tested in vitro
in mouse and GK rat islets and in vivo in the GK rat [24].
Indeed, increased islet-derived inflammatory factors [IL-6,
chemokine KC, G-CSF, MIP-1α and MCP-1 (monocyte
chemoattractant protein 1)] due to a diabeticmilieu in vitro or
in vivo (GK rat) could be reversed by pancreatic islet IL-1RA
treatment in vitro. Furthermore, using IL-1β-knockoutmice,
the effect of IL-1RA was confirmed to be specific to IL-1β
[24]. Finally, treatment of theGK rat, a spontaneousmodel of
Type 2 diabetes,with IL-1RAreversed this islet inflammatory
phenotype in vivo and reduced hyperglycaemia (J.A. Ehses
and colleagues, unpublished work). Thus IL-1β appears to Q1
be a master regulator of islet inflammation in Type 2 diabetes.
Clinical consequences
Understanding that a key role of IL-1β in the pathogenesis
of diabetes is to regulate the pancreatic β-cell, and given the
availability of the human recombinant IL-1RA,we conducted
a clinical trial of IL-1 receptor antagonism in Type 2 diabetes
[25]. A total of 70 patients were randomized to subcutaneous
injection of anakinra once daily or placebo. At 13 weeks,
glycated haemoglobin was significantly lower in the anakinra
than in the placebo group. β-Cell secretory function was
enhanced, and there was a reduction in the proinsulin to
insulin ratio, an indicator of β-cell stress. As highlighted
recently [26], this might be a disease-modifying treatment for
Type 2 diabetes and the next generation of mechanistically
targeted therapeutic agents. Ongoing and planned studies
will evaluate the benefit of IL-1 antagonists with prolonged
half-lives, allowing weekly or monthly injections, and
therefore greater improvement of glucose metabolism.
Summary and working hypothesis
On the basis of the above, we propose a hypothesis for the
development of islet inflammation in Type 2 diabetes, and
consecutive failure to produce sufficient insulin (Figure 1).
According to this hypothesis, metabolic stress (high glucose
and non-esterified fatty acids) and leptin [27] induce β-cell
production of IL-1β. Locally produced IL-1β will enhance
its own production via auto-induction in addition to inducing
production of inflammatory factors, including IL-8. This
will attract macrophages which may become activated in a
paracrine manner by islet-derived cytokines, such as IL-1β.
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Figure 1 Islet inﬂammation in Type 2 diabetes
For explanation, see the Summary and working hypothesis section in
the text.
In turn, activated macrophages will produce even more
IL-1β, which will contribute to β-cell secretory failure and
death. This may be precipitated by unprocessed amyloid
[16,17], which will accumulate into post-inflammatory
fibrotic deposits.
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